Virtual Meetings 2022

Meet The Professor: Non-Small Cell Lung Cancer with an Actionable
Target Beyond EGFR

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado, Anschutz Medical Campus
Denver, Colorado

Alexander E Drilon, MD
Chief, Early Drug Development Service
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York



Justin F Gainor, MD
Director, Center for Thoracic Cancers at Massachusetts General Hospital
Director of Targeted Immunotherapy in the
Henri and Belinda Termeer Center for Targeted Therapies
Associate Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Melissa Johnson, MD
Director, Lung Cancer Research Program
Associate Director of Drug Development for the Drug Development Unit in Nashville
Sarah Cannon Research Institute
Nashville, Tennessee

Additional faculty to be announced.

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Elevation Oncology Inc, Genentech, a member of the Roche Group, Novartis and Turning Point Therapeutics Inc.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for non-small cell lung cancer (NSCLC) with an actionable target beyond EGFR. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Treatment Selection for Patients with NSCLC and an ALK or ROS1 Rearrangement

    MODULE 2: Rational Approaches to Targeting MET Abnormalities in Patients with NSCLC

    MODULE 3: Integration of Novel RET Inhibitors into Current Management Algorithms

    MODULE 4: KRAS, HER2 and Other Potential Targets in NSCLC

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of non-small cell lung cancer with an actionable target beyond EGFR.

Learning Objectives

  • Recognize the spectrum of oncogenic alterations beyond those associated with EGFR identifiable in patients with non-small cell lung cancer (NSCLC), and determine how these may predict potential response to novel targeted therapies.
  • Appraise the efficacy and safety of approved and investigational ALK inhibitors, and determine how these agents can be integrated into the protocol and nonresearch care of patients with NSCLC with ALK rearrangements.
  • Consider the mechanism of action of entrectinib, available data and the FDA approval of that agent for patients with NSCLC with ROS1 alterations, and discern how it can be appropriately and safely integrated into routine clinical care.
  • Assess available clinical trial findings supporting the FDA approvals of capmatinib and tepotinib for metastatic NSCLC with MET exon 14 skipping mutations, and identify patients who might benefit from these agents.
  • Recall the FDA approvals of selpercatinib and pralsetinib for patients with RET-driven metastatic NSCLC, and evaluate how these agents should be appropriately and safely integrated into clinical practice.
  • Recollect other oncogenic pathways (ie, HER2, KRAS) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
  • Recognize common and rare side effects associated with novel targeted agents employed in the treatment of NSCLC, and use this information to develop supportive management plans for patients.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies for patients with NSCLC harboring actionable mutations beyond EGFR, and offer counsel about the potential benefits of trial participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr CamidgeAdvisory Committee: Apollomics Inc, AstraZeneca Pharmaceuticals LP, Elevation Oncology, Kestrel Lifesciences, Nuvalent; Consulting Agreements: AbbVie Inc, Amgen Inc, AnHeart Therapeutics, Blueprint Medicines, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Medtronic Inc, Mersana Therapeutics Inc, Mirati Therapeutics, OnKure Therapeutics, Ribon Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd, Biothera Pharmaceuticals Inc, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Lilly; Stock: Kestrel Lifesciences; Other: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Mersana Therapeutics Inc (ILD adjudication committee); Puma Biotechnology Inc (NCCN grant review). Dr DrilonAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Elevation Oncology, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Ignyta Inc, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Medendi Inc, Monopteros Therapeutics, Novartis, Pfizer Inc, Repare Therapeutics; Consulting Agreements: AbbVie Inc, Applied Pharmaceutical Science Inc, AstraZeneca Pharmaceuticals LP, Axis Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BerGenBio ASA, Blueprint Medicines, Entos Pharmaceuticals, EPG Health, Genentech, a member of the Roche Group, Harborside, Hengrui Therapeutics Inc, Ignyta Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Liberum Biotech, Merus BV, MBRACE Therapeutics, Nuvalent, Ology Bioservices, Pfizer Inc, Prelude Therapeutics, Tyra Biosciences; Contracted Research: Exelixis Inc, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Chugai Pharmaceutical Co Ltd, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Ignyta Inc, Liberum Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Remedica Ltd, RV More, TP Therapeutics Inc, Verastem Inc; Other: Boehringer Ingelheim Pharmaceuticals Inc, Merck, Merus BV, Puma Biotechnology Inc; Financial relationships with organizations not considered ineligible companies by the ACCME: Treeline Biosciences Inc (stock ownership). Dr GainorConsulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals. Dr JohnsonConsulting Agreements (All to Institution): AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Axelia Oncology, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Checkpoint Therapeutics Inc, CytomX Therapeutics, Daiichi Sankyo Inc, EcoR1 Capital LLC, Editas Medicine, Eisai Inc, EMD Serono Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gritstone Oncology, IDEAYA Biosciences, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics, Oncorus, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Sanofi Genzyme, Turning Point Therapeutics Inc, WindMIL Therapeutics; Contracted Research (All to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene Ltd, BerGenBio ASA, BioAtla, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax, Elicio Therapeutics, EMD Serono Inc, Erasca, Genentech, a member of the Roche Group, Genmab, Genocea, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences Inc, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Memorial Sloan Kettering Cancer Center, Merck, Mirati Therapeutics, NeoImmuneTech, Neovia Oncology, Novartis, Numab, Nuvalent, OncoMed Pharmaceuticals Inc, Pfizer Inc, PMV Pharma, Rain Therapeutics, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi Genzyme, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Silicon Therapeutics, Stemcentrx, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics Inc, Turning Point Therapeutics Inc, University of Michigan, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc.

SURVEY PARTICIPANTSChristina Baik MD, MPHConsulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Guardant Health, Regeneron Pharmaceuticals Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Pfizer Inc, Rain Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Elevation Oncology Inc, Genentech, a member of the Roche Group, Novartis and Turning Point Therapeutics Inc.